The Guardian Hemgenix is a new FDA approved drug that will let patients stop receiving IVs. Instead, they can receive one infusion, which could dramatically decrease bleeding events. Hemgenix may be beneficial for up to 94% of hemophilia A patients. Although hemophilia A tends to be more common, 16 million Americans have hemophilia. This treatment may help reduce anxiety and fears about potentially dangerous bleeding events.
After two favorable studies that showed hemophilia A (via), Hemgenix was recommended by FDA. CNN). Peter Marks MD, PhD is the director of The Center for Biologics Evaluation and Research. He said this in FDA issues statement, “Today’s approval provides a new treatment option for patients with hemophilia B and represents important progress in the development of innovative therapies for those experiencing a high burden of disease associated with this form of hemophilia.” Zynteglo (a drug used to treat beta thalessemia, was prior to Hemgenix). The cost was $2.8 million.